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Background: There is a significant resumption of smoking following smoking cessation using varenicline. Both
smoking cessation medications and counseling have been shown to increase smoking quit rates at one year. Thus,
the combination of varenicline and interactive voice response (IVR) telephony followed by extended IVR may
further improve smoking cessation rates at one and two years.
Methods: 101 participants were recruited from the community via newspaper advertisement. They attended a
group counseling session and were given smoking information booklets from the Canadian Cancer Society.
After 12 weeks of varenicline and 9 IVR calls, all participants who had quit smoking were randomized into 2 groups
matched by levels of motivation and addiction as per baseline questionnaire score. The intervention group
continued to receive bi-weekly IVR support for weeks 13 – 52. The control group no longer received IVR. The
primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 ppm for weeks
12, 52 and 2 years. Data were analyzed by Fisher’s exact test or Wilcoxon rank-sum test.
Results: Of the 101 participants, 44 (43%) had stopped smoking after 12 weeks of varenicline and 9 IVR calls. Of
these, 23 (52%) were randomized to receive IVR calls from weeks 13 to 52.
At 52 weeks, 26 (59%) participants remained smoke-free. Of the 23 with IVR, 12 (52.2%) stopped smoking compared
to 14 of 21 (66.7%) without IVR. At 2 years, 40 of the 44 (90.9%) randomized participants were contacted and 24 of
the 44 (54.5%) came in for testing. Fourteen (13% of the original cohort, 30% who were abstinent at 12 weeks and
53% who were abstinent at 52 weeks) remained smoke-free. Five of the 23 (21.7%) randomized to IVR and 9 of the
21 (42.9%) randomized to no IVR remained smoke-free at 2 years.
Conclusions: In this pilot study of an apparently healthy population, extended IVR did not affect abstinence rates.
There was no relapse prevention benefit in offering 9 months of continued IVR to subjects who had stopped
smoking after receiving 3 months of varenicline and IVR treatment.
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When administered for 12 weeks, the smoking cessation
drug varenicline has been shown to lead to continuous ab-
stinence rates of about 44% during the last 4 weeks of
treatment and 22 – 23% at a one-year follow-up [1,2]. Al-
though varenicline’s effect exceeded that of other drugs
such as sustained-release bupropion, the cessation rates
are still low. While medications can be effective in redu-
cing withdrawal symptoms and improving treatment out-
comes, a combination of pharmacotherapy and behavioral
counseling is more likely to increase abstinence rates [3].
IVR systems have been applied in a variety of medical
settings and have been used successfully to assess pa-
tients at home after hospital discharge for adverse out-
comes [4].
Three Canadian studies have explored the potential of
IVR to follow smokers after discharge as part of a
comprehensive hospital-based smoking intervention (the
“Ottawa Model”), demonstrating that it is feasible to use
IVR in this setting and suggesting an intervention that
includes optional automated post-discharge follow-up
may increase smoking cessation. However, the specific
contribution of IVR to cessation rates was assessed only
in a small pilot study limited to smokers admitted with
myocardial infarction. The study showed a benefit of
IVR that did not reach statistical significance. Also, car-
diac patients have higher rates of smoking cessation after
hospital discharge than a general population [4].
The automated IVR uses algorithms and computerized
speech recognition to engage smokers on the telephone: it
gathers information; provides reinforcing messages and tri-
ages them to a study nurse for call-back within 2 working
days if either the smoker or the nurse identify that help is
required. IVR is a low cost, high-yield way of contacting
smokers when they would not ordinarily be contacted.
In our study everyone received a combination of medi-
cation and smoking cessation counseling (through the
IVR and call-back), from a study nurse if needed. This
combination approach gave all participants proven treat-
ment and an equal opportunity to stop smoking. We hy-
pothesized that IVR telephony may decrease the relapse
rate after smoking cessation.
Methods
Ethics and study design
This investigator initiated study was sponsored by Pfizer
Canada, producers of varenicline. The study was scruti-
nized internally at the Healthy Heart Program and also
by scientists at Pfizer Canada and Pfizer United States of
America. It was approved by the Providence Health Care
Ethics Committee.
The study is a two-arm, randomized pilot study of
2 years duration to determine the effect of 9 months of
extended IVR on the effectiveness of smoking cessationafter an initial 3 months of varenicline and IVR treat-
ment. The randomized component of the study included
only those who successfully quit smoking at 12 weeks.
Varenicline has been approved by Health Canada and
marketed since 2007. The IVR system includes the op-
tion of direct nurse-to-subject over the telephone coun-
seling. Both the automated IVR system and the direct
nurse-to-subject over the telephone contact are classified
as counseling.
The IVR uses algorithms and speech recognition to
collect information from participants and monitor symp-
toms. It provides encouragement and reinforcing smoking
cessation messages. These regular messages may serve to
further strengthen participants’ sense of self-efficacy in
remaining smoke-free [5]. If the participant requests a
call-back then a study nurse would call them and help
them get back on track with smoking cessation.
Short counseling interventions have been found to be
very effective. Callback counseling provides a flexible, cost-
effective intervention for smoking cessation that can be
provided by a centralized service for a large population. It
appears to encourage a greater proportion of quit attempts
and to reduce the rate of relapse among those quitting [6].
Study population
101 participants were recruited from the community in
response to an advertisement in a local newspaper. None
had a history of cardiac or other chronic disease.
Inclusion criteria: smoking 35 or more cigarettes per
week or 5 or more cigarettes per day for at least 2 years
with no period of abstinence longer than 3 months.
Exclusion criteria: use of any smoking cessation drugs
or nicotine replacement drugs in the last 3 months, use of
medications to treat depression or any psychiatric illness,
history of depression or an unstable medical condition.
Exclusion criteria were identified by self-report. The
study investigators met with each participant to complete
a checklist of inclusion and exclusion criteria as approved
by the hospital ethics committee. None of the participants
who attended the initial study information session had a
chronic disease. Those who had experienced depression
or had a mental health condition in the past year were
excluded because of the varenicline warning label for agi-
tation, hostility, depression or changes in behaviour or
thinking. We excluded people who had experienced these
symptoms in the past year.
All potential participants attended an information ses-
sion about smoking, smoking cessation, varenicline,
eligibility for the study, and the relevance of the ques-
tionnaire about demographics, motivation, stress, and
smoking. They were given an information package
including the Canadian Cancer Society booklets For
Smokers Who Don’t Want to Quit and For Smokers Who
Want to Quit.
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The study was performed in the Healthy Heart Pro-
gram, an outpatient clinic. The focus of the program is
helping people minimize their risk factors for coronary
artery disease.
Initial varenicline and IVR treatment
Participants received a 12-week supply of varenicline:
0.5 mg to be taken on days 1–3, 0.5 mg twice a day on
days 4–7, and 1 mg twice a day until the end of week
12. At the initial visit participants chose a target quit
date between 8 and 14 days after starting varenicline and
gave their preferred calling time for the IVR technology.
The IVR intervention consisted of 2 parts: establishing
it is speaking to the study participant and the main data
collection section. As instructed at the beginning of the
call, the participant answers “yes” or “no” to all questions
except when asked about their level of confidence and
their side effects. The IVR asks if they have had a
cigarette since their quit date, if they have smoked a
cigarette, even a puff, if they have used varenicline in the
last 14 days, have they experienced any side effects, how
confident they are that they will remain a non-smoker,
and would they like to have a study nurse call them to
help prevent relapse or provide advice about varenicline.
Finally, there is a positive reinforcing message thanking
and congratulating them followed by “remaining smoke-
free is the single most important thing you can do for
your health”. The calls are 3–5 minutes long, depending
on their answers and which part of the algorithm they
are directed to. The IVR made a call on their quit day,
then on day 3, 8, and 11, and every 2 weeks thereafter.
After the 12th week of treatment, those who had stopped
smoking were asked to come in for an exhaled carbon
monoxide level measurement to confirm their non-
smoking status. The primary end-point was self-reported
abstinence and exhaled carbon monoxide levels of less than
10 parts per million (ppm) at 12 and 52 weeks and 2 years.
Intervention and control cohorts
Participants who had quit smoking at 12 weeks were
randomized into 2 groups matched by their level of mo-
tivation and level of addiction as per psychometric ques-
tionnaire at baseline. This was a stratified randomization
whereby participants were categorized by motivation
and addiction. The intervention group continued to re-
ceive IVR calls every 2 weeks from weeks 13 – 52. The
control group did not receive further IVR.
At 52 weeks, all participants were asked to come in for
a follow-up appointment and complete the same ques-
tionnaire administered at the initial baseline visit. Weight
and waist circumference were measured and in those who
had stopped smoking an exhaled carbon monoxide level
was measured.At 2 years all participants were asked to come in for a
final visit to measure weight and waist circumference and
determine smoking status. For those who were not smok-
ing an exhaled carbon monoxide level was measured.Analysis
To date, a single all-encompassing questionnaire to as-
sess level of motivation to stop smoking has not been
developed. Rather, it is agreed that assessment of nico-
tine dependence, stage of change, balance of pros and
cons, level of temptation, confidence to stop smoking,
and level of stress and mood is best used in combination
to assess motivation [7-9].
Questionnaire data were collected at the initial and
52 week visit. The Stage of Change algorithm was used
to determine the stage of readiness for change [10]. Pros
and cons of change were assessed using the Decisional
Balance Scale [11]. This measured participants’ perceived
benefits and drawbacks of stopping smoking. Their self-
efficacy was measured on the Self-Efficacy and Tempta-
tion Scale [12]. These questionnaires have been used in
the Canadian Heart and Stroke Foundation funded trial –
The Multicentre Biofeedback Reactivity Trial: Modifying
Cardiovascular Reactivity to Stress During the Acute
Phase of Smoking Cessation [13].
The Fagerstrom Tolerance Test of Nicotine Dependence
was used to determine level of dependence on nicotine
and The Stop D Scale (Stress and Mood) to provide se-
verity scores for each of the following areas: depression,
anxiety, stress, anger, and poor social support [14,15].
The answers to the questionnaire provide information
about the phenotype – who responds to varenicline and
IVR treatment and who does not.
Motivation is a complex subject that involves motives,
intents, values, and probability of success [16]. Motiv-
ation is considered critical to changing problem behav-
iours and to engaging in health-protection behaviours
such as stopping smoking. Motivation for change typic-
ally refers to both reasons for change and the strength of
the desire or commitment to make the change [17].
Age, gender, income, social support and number of
cigarettes smoked per day are among the factors that
have been shown to influence ability to stop smoking
[18,19]. Table 1 summarizes selected variable frequencies
that were included in the questionnaires. These are the
variables with the strongest trend toward significance.Statistical analysis
Summary statistics were used to describe the demo-
graphic characteristics of the study participants. The
univariate relationship between the outcome and the po-
tential predictors were analyzed by Fisher’s exact test or
Wilcoxon rank-sum test as appropriate.
Table 1 Summary of selected variable frequencies














Median (IQR) 54.0 (45.0, 62.0)
Mean (SD) 52.6 (11.8)
Min & max (25.0, 73.0)
Weight at baseline (kg)
Median (IQR) 76.4 (66.6, 90.7)
Mean (SD) 78.8 (16.6)
Min & max (48.4, 136.0)
Waist at baseline (cm)
Median (IQR) 91.0 (83.0, 100.0)
Mean (SD) 92.8 (13.9)
Min & max (44.5, 134.0)
Number of cigs. smoked per day at baseline
Missing data 1
Median (IQR) 18.0 (13.0, 22.0)
Mean (SD) 19.2 (9.8)
Min & max (6.0, 55.0)
Status at week 12
Still smoking 57 (56.4%)
Not smoking 44 (43.6%)
Status at week 52
Missing data 33 (.%)
Smoking 40 (58.8%)
Not smoking 27 (39.7%)
Died 1 (1.5%)
Randomized to extended IVR
No 21 (47.7%)
Yes 23 (52.3%)
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Of the 101 participants, 44 (43%) had stopped smoking
after 12 weeks of varenicline and 9 IVR calls. Of these
44 subjects, 23 (52%) were randomized to receiveextended IVR calls from weeks 13 to 52 and 21 (48%)
were in the control group. Table 2 provides the selected
variable frequencies in subjects eligible for randomization
at week 12 (n = 44).
Of the 44 participants who had quit smoking at
12 weeks, 26 (59%) remained smoke-free at 52 weeks, 12
of these had received extended IVR and 14 were in the
control group (12/23 (52%) vs. 14/21 (66.7%); p = 0.33).
Table 3 provides the status at 52 weeks for those eligible
for randomization at week 12 (n = 44).
One participant who was not randomized stopped
smoking after surgery for lung cancer. As a result, there
were 27 confirmed non-smokers at 52 weeks but only 26
had been randomized at 12 weeks. One participant was
diagnosed with lymphoma, randomized to receive ex-
tended IVR and remained a non-smoker at 52 weeks,
and one participant who failed to quit at 12 weeks, died
from an AIDS related illness.
At 2 years, 40 (39%) of the original 101 participants
were contacted and 24 (23%) had their carbon monoxide
measured. There were 14 (13% of the study population,
30% of those abstinent at 12 weeks, 53% of those abstin-
ent at 52 weeks) who were confirmed non-smokers. Of
these, 5 (21% of those abstinent at 12 weeks) had re-
ceived extended IVR. Thus, 5 of 23 (21.7%) on IVR
versus 9 of 21 (42.9%) on no IVR (chi-square = 2.26, p =
0.13) remained smoke-free at two years. Figure 1 displays
a summary flowchart of the study results at 12 weeks, 1
and 2 years.
The IVR responses did identify those who were strug-
gling to stop smoking and these were the participants
that were called back. There were no common psycho-
social or demographic characteristics, as identified in the
questionnaire, that indicated who would respond to the
IVR calls and who would not.
For participants in the extended IVR group, week 12 –
52, there was a low percentage of IVR calls completed
(mean 37%, median 34%) and a lower percentage of as-
sessments completed (mean 16%, median 16%). These
were the participants who had stopped smoking at
12 weeks and were the subject of investigation.
Variables predicting smoking cessation
Our study participants were recruited from the commu-
nity, while many studies included recently hospitalized
subjects who may have a greater degree of motivation to
stop smoking.
Income over $54,000. showed a trend toward im-
proved smoking cessation rates but was not statistically
significant.
Table 4 displays a summary of the association between
potential predictors and smoking status at week 12.
Table 5 displays a summary of these potential predictors
at week 52.







Male 14 (66.7%) 13 (56.5%)
Female 7 (33.3%) 10 (43.5%)
Present living status
Married 7 (33.3%) 12 (52.2%)
Cohabiting 1 (4.8%) 2 (8.7%)
Coupled and not cohabiting 0 (0.0%) 1 (4.3%)
Widowed 2 (9.5%) 2 (8.7%)
Separated 1 (4.8%) 0 (0.0%)
Divorced 3 (14.3%) 3 (13.0%)
Single 7 (33.3%) 3 (13.0%)
Age at baseline
Median (IQR) 57.0 (48.0, 61.0) 58.0 (50.0, 64.0)
Mean (SD) 54.2 (10.0) 55.7 (10.9)
Min & max (30.0, 69.0) (27.0, 73.0)
Weight at baseline (kg)
Median (IQR) 72.5 (64.4, 84.0) 76.4 (67.7, 98.3)
Mean (SD) 74.7 (13.6) 83.3 (21.6)
Min & max (55.1, 105.7) (48.4, 136.0)
Waist at baseline (cm)
Median (IQR) 91.0 (83.0, 98.0) 95.0 (87.0, 106.0)
Mean (SD) 90.7 (11.4) 98.4 (15.4)
Min & max (71.0, 117.5) (79.0, 134.0)
Number of cigs. smoked per day at baseline
Median (IQR) 16.0 (10.0, 20.0) 18.0 (13.0, 22.0)
Mean (SD) 17.3 (8.6) 18.5 (6.6)
Min & max (6.0, 40.0) (7.0, 37.0)
Abstinent at 12 weeks 
n = 44 
Abstinent – no further IVR 
n = 21 
Abstinent – IVR weeks 13 – 52 
n = 23 
Abstinent at 52 weeks 
n = 12/23 
Abstinent at 52 weeks 
n = 14/21 
Abstinent at 52 weeks 
n = 26 
Abstinent at 2 years 
n = 14/24 
Abstinent at 2 years 
n = 9/14 
Abstinent at 2 years 
n = 5/10 
12 weeks of 
Champix & IVR 
Participants 
n = 101 
Figure 1 Flow chart.
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The study had a unique design and a long (2 year)
follow-up.
The major appeals of using IVR are its high level of
accessibility, and cost-effectiveness. Telephones are sim-
ple to use and familiar to people of most demographics,Table 3 Status at 52 weeks for those eligible for








Status at week 52
Missing 4 2 2 0.333
Smoking 14 (35.0%) 5 (26.3%) 9 (42.9%)
Not smoking 26 (65.0%) 14 (73.7%) 12 (57.1%)
1Based on Fisher’s exact test.an advantage of IVR over some of the similar internet-
based approaches that are currently being employed [5].
Research has shown that levels of IVR compliance
tends to be relatively high when used for symptom mon-
itoring and as an adjunct to the treatment of chronic
pain [5]. This may indicate that IVR technology works
well for people when they feel that it is beneficial and
they are motivated to reach an outcome such as pain
management.
Cardiac patients also have higher rates of smoking ces-
sation after hospital discharge than a general population
[4]. A study from The Ottawa Heart Institute identified
almost 1300 patients at admission and 91% received inter-
vention to help them quit smoking. Six months after dis-
charge 44% of cardiac patients were not smoking after
10 weeks of nicotine patch therapy and 3 IVR calls [20].
A study with a general population showed after
12 weeks of varenicline or 10 weeks of transdermal
nicotine patch, the last 4 weeks of treatment showed a
significantly greater abstinence rate with varenicline
(55.9%) than transdermal nicotine patch (43.2%; OR
1.70, 95% CI 1.26 to 2.28, p < 0.001). At 52 weeks these
numbers decreased to 26.1% for varenicline and 20.3%
for transdermal nicotine patch (OR 1.40, 95% CI 0.99 to
1.99, p = 0.056) [21].
Table 4 Association between potential predictors and







Missing 1 (.%) 0 (.%)
Male 40 (59.7%) 27 (40.3%)
Female 16 (48.5%) 17 (51.5%)
Present living status 0.554
Married/Cohabiting 32 (59.3%) 22 (40.7%)
Single/Others2 25 (53.2%) 22 (46.8%)
Age at baseline 0.104
Median (IQR) 52.0 (40.0, 61.0) 57.5 (49.0, 63.0)
Mean (SD) 50.8 (12.6) 55.0 (10.4)
Min & max (25.0, 70.0) (27.0, 73.0)
Weight at baseline (kg) 0.856
Median (IQR) 77.2 (66.7, 90.7) 75.4 (64.8, 90.2)
Mean (SD) 78.5 (15.0) 79.2 (18.5)
Min & max (50.2, 109.5) (48.4, 136.0)
Waist at baseline (cm) 0.319
Median (IQR) 91.0 (82.5, 99.0) 92.3 (85.3, 101.5)
Mean (SD) 91.3 (13.7) 94.7 (14.0)
Min & max (44.5, 127.0) (71.0, 134.0)
Number of cigs. smoked per day at baseline 0.467
Median (IQR) 20.0 (14.0, 23.0) 18.0 (13.0, 20.0)
Mean (SD) 20.2 (11.2) 18.0 (7.6)
Min & max (6.0, 55.0) (6.0, 40.0)
1Depending on the type of the variable, p-value is based on Fisher’s exact test
or Wilcoxon rank-sum test.
2Others include widowed, separated, divorced and coupled (not cohabiting).
Table 5 Association between potential predictors and






Treatment group 0 .333
Control 5 (26.3%) 14 (73.7%)
Extended IVR 9 (42.9%) 12 (57.1%)
Sex 0.736
Male 8 (32.0%) 17 (68.0%)
Female 6 (40.0%) 9 (60.0%)
Present living status 0.510
Married/Cohabiting 6 (28.6%) 15 (71.4%)
Single/Others2 8 (42.1%) 11 (57.9%)
Age at baseline 0.966
Median (IQR) 57.5 (50.0, 63.0) 59.0 (48.0, 64.0)
Mean (SD) 56.3 (8.5) 55.3 (11.8)
Min & max (41.0, 69.0) (27.0, 73.0)
Weight at baseline (kg) 0.092
Median (IQR) 69.7 (64.2, 77.4) 80.9 (68.1, 91.5)
Mean (SD) 72.9 (15.4) 82.4 (19.8)
Min & max (55.1, 111.0) (48.4, 136.0)
Waist at baseline (cm) 0.072
Median (IQR) 87.8 (83.0, 95.0) 96.5 (89.0, 103.5)
Mean (SD) 90.1 (13.6) 97.3 (13.9)
Min & max (71.0, 125.5) (72.5, 134.0)
Number of cigs. smoked
per day at baseline
0.493
Median (IQR) 19.0 (12.0, 25.0) 17.0 (13.0, 20.0)
Mean (SD) 18.9 (8.4) 16.9 (7.3)
Min & max (7.0, 37.0) (6.0, 40.0)
1Depending on the type of the variable, p-value is based on Fisher’s exact test
or Wilcoxon rank-sum test.
2Others include widowed, separated, divorced and coupled (not cohabiting).
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compares with our 43% quit rate after 3 months of
vareniclince and IVR. At 52 weeks the 26.1% quit rate
compares with 25% of our original group (n = 26 out of
101). The quit rates for dual therapy varenicline and IVR
were lower at 3 months in our study than for monother-
apy varenicline.
While our study had a small sample size, it was inter-
esting that those who were not smoking at 12 weeks and
received extended IVR from weeks 13 – 52 had a 52.5%
quit rate at 52 weeks. Those who were not smoking at
12 weeks and did not receive extended IVR had a 66.7%
quit rate. It would appear that if you are able to quit by
12 weeks with varenicline and IVR you have a higher
likelihood of not smoking at 52 weeks than if you had
stopped with use of varenicline alone.
Relapse prevention
The Cochrane Review for “relapse prevention interventions
for smoking cessation” found that there is insufficientevidence, at the moment, to support the use of any specific
behavioural intervention for helping smokers who have
successfully quit for a short time to avoid relapse. The ver-
dict is strongest for interventions focusing on identifying
and resolving tempting situations, as most studies were
concerned with these. There is little research available
regarding other behavioural approaches. However, ex-
tended treatment with varenicline (past 12 weeks) may
prevent relapse [22].
All participants in the study consented to receiving
IVR calls. As IVR and varenicline were the basis of the
study protocol it is difficult to determine how many were
motivated to participate in IVR contact. There were no
predictors (age, gender, number of cigarettes smoked per
day) at 12 and 52 weeks as to who would respond to the
IVR calls. Also, for those who had quit smoking at
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calls between week 12 and 52, there were no predictors.
The IVR initiates contact as opposed to Quit Lines
that people call. If participants request a call back or if
their IVR responses indicate they are struggling with
remaining smoke-free, are smoking, or experiencing side
effects, a study nurse calls them. Proactive telephone
counseling not initiated by calls to helplines helps smokers
interested in quitting (44 studies, >24,000 participants, RR
1.29, 95% CI 1.20 to 1.38) [4].
There is some evidence of a dose response; one or two
brief calls are less likely to provide a measurable benefit.
Three or more calls increase the chances of quitting
compared to a minimal intervention such as providing
standard self-help materials, brief advice, or compared
to pharmacotherapy alone. Telephone quitlines provide
an important route of access to support for smokers,
and call-back counseling enhances their usefulness [23].
In our study, participants received 9 IVR calls in the
first 12 weeks and those who were randomized to re-
ceive extended IVR from weeks 13 – 52 received an add-
itional 19 calls. We are not aware of any studies with
this many IVR calls for this long of a period.
While relapse was progressive from week 13 through
52, those who had quit with IVR and varenicline at
12 weeks had relatively low relapse rates for smoking
cessation by 52 weeks. Interestingly, those who had quit
at 12 weeks (43%) and went on to receive extended IVR
had a 52.5% quit rate at 52 weeks (n = 12/23). Those
who had quit at 12 weeks and did not receive further
care had a 66.7% quit rate (n = 14/21).
Future studies will hopefully address the possibility of an
inverse benefit ratio of, for example, receiving more than 9
IVR calls. To our knowledge, there have been no pub-
lished trials providing IVR and telephone call-back coun-
seling as an adjunct to varenicline for smoking cessation.
We were not able to follow-up with study subjects to
find out why they lost interest with the IVR.
The time of year chosen for follow-up may not have
been conducive to attending follow-up appointments
and responding to IVR calls. Follow-up appointments
were scheduled at 12 weeks, 52 weeks and 2 years. All of
these times coincided with summer season which may
have been a barrier to attending. Also, the opportunity to
receive the varenicline at no charge may have attracted a
select population. The study participants were a lower in-
come group ($42,000. average annual income) than the
provincial average ($67,000). Other studies have shown a
link between lower average income and ability to stop
smoking [24,25].
Conclusions
Our data show a lack of significant reduction in relapse
rates at 52 weeks in apparently healthy participants whohad received extended IVR (weeks 12 – 52) after
stopping smoking with an initial 12 week treatment of
varenicline and IVR.
Although age, treatment, baseline weight and income
showed trends as predictors of smoking cessation, they
were not statistically significant. These findings suggest a
larger study is needed before allocating health care funds
for IVR in a healthy population without chronic disease.
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